Hsbc Holdings PLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 357,022 shares of the medical equipment provider’s stock after selling 9,335 shares during the quarter. Hsbc Holdings PLC’s holdings in Zimmer Biomet were worth $32,151,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. DV Equities LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $30,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $31,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $32,000. Finally, Grove Bank & Trust raised its position in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 328 shares during the last quarter. 88.89% of the stock is owned by institutional investors.
Insider Activity at Zimmer Biomet
In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is currently owned by corporate insiders.
Zimmer Biomet Stock Performance
Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter in the previous year, the company earned $1.81 earnings per share. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.
Zimmer Biomet Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is 24.94%.
Wall Street Analysts Forecast Growth
ZBH has been the topic of a number of recent research reports. Citizens Jmp decreased their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Citigroup cut their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Truist Financial reiterated a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Barclays cut their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $102.70.
Read Our Latest Stock Analysis on ZBH
Zimmer Biomet Profile
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.
Featured Stories
- Five stocks we like better than Zimmer Biomet
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
